The objective of this study is to evaluate the initial safety and preliminary effectiveness of the Obalon intragastric balloon system in European subjects with a BMI in the range of 27 - 35 kg/m\^2
Study Type
OBSERVATIONAL
Enrollment
17
Department of Gastroenterology, Erasme Hospital
Brussels, Belgium
Service D'exploration Functionelle Digestive, Hospital Edouard Harriot
Lyon, Cedex, France
Percent Excess Weight Loss based on an ideal BMI of 25.
Time frame: 12 weeks
Assessment of all adverse events.
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.